Personalis, Inc. (NASDAQ:PSNL) Receives $7.42 Consensus Price Target from Analysts

Key Points

• Personalis, Inc. has received an average recommendation of "Buy" from five research firms, with a 12-month price target estimate of $7.42.
• The company recently reported a quarterly earnings per share of ($0.23), beating estimates, but had a negative net margin of 113.70%.
• Institutional investors own 61.91% of Personalis's stock, with significant increases in holdings from several firms, including ARK Investment Management and Geode Capital Management.

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $7.4167.

Several equities research analysts recently weighed in on PSNL shares. Wall Street Zen raised shares of Personalis from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright reissued a "buy" rating and set a $8.50 price objective on shares of Personalis in a research report on Monday, September 8th. Finally, BTIG Research set a $6.00 target price on shares of Personalis in a report on Wednesday, August 6th.

Personalis Stock Performance

Shares of Personalis stock traded up $0.28 on Wednesday, reaching $6.10. The company had a trading volume of 1,454,507 shares, compared to its average volume of 812,917. Personalis has a 52-week low of $2.83 and a 52-week high of $7.79. The firm's 50 day moving average price is $5.41 and its two-hundred day moving average price is $4.92. The firm has a market cap of $540.95 million, a PE ratio of -4.77 and a beta of 1.76.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in shares of Personalis in the second quarter valued at about $30,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Personalis during the fourth quarter worth about $28,000. Ameritas Investment Partners Inc. acquired a new position in Personalis during the second quarter worth about $34,000. BNP Paribas Financial Markets raised its position in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, Alpha Wealth Funds LLC acquired a new position in Personalis during the second quarter worth about $66,000. Institutional investors and hedge funds own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.